Skip to main content

Moberg Pharma regains full rights to MOB-015 in Japan

STOCKHOLM, March 9[th], 2023, Moberg Pharma AB (OMX: MOB) today announces that Taisho Pharmaceutical Co., Ltd and Moberg Pharma terminate the license agreement for development, registration and commercialization of MOB-015 in Japan. Moberg Pharma regains full rights to the product in Japan and retains milestone revenues paid by Taisho.

Taisho has conducted an extensive review on its R&D pipeline and decided to stop the development on MOB-015 due to strategic reasons. Therefore, Moberg Pharma now regains the full rights for MOB-015 in Japan.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, E-mail:

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 9th, 2023, at 8.00 am CEST.

About Moberg Pharma,
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Canada, among others, and the Company's goal is to receive its first market approval and launch MOB-015 in 2023. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).